{"url":"https://lda.senate.gov/api/v1/filings/fdff7e33-b7f3-4cec-978d-5c58fe0476e7/","filing_uuid":"fdff7e33-b7f3-4cec-978d-5c58fe0476e7","filing_type":"Q2","filing_type_display":"2nd Quarter - Report","filing_year":2022,"filing_period":"second_quarter","filing_period_display":"2nd Quarter (Apr 1 - June 30)","filing_document_url":"https://lda.senate.gov/filings/public/filing/fdff7e33-b7f3-4cec-978d-5c58fe0476e7/print/","filing_document_content_type":"text/html","income":null,"expenses":"290000.00","expenses_method":"A","expenses_method_display":"A","posted_by_name":"Christopher Porter","dt_posted":"2022-07-19T07:59:16-04:00","termination_date":null,"registrant_country":"United States of America","registrant_ppb_country":null,"registrant_address_1":"3611 Valley Centre Drive","registrant_address_2":"Suite 300","registrant_different_address":true,"registrant_city":"San Diego","registrant_state":"CA","registrant_zip":"92130","registrant":{"id":401104190,"url":"https://lda.senate.gov/api/v1/registrants/401104190/","house_registrant_id":null,"name":"TRAVERE THERAPEUTICS","description":"Pharmaceuticals","address_1":"3611 Valley Centre Drive","address_2":"Suite 300","address_3":null,"address_4":null,"city":"San Diego","state":"CA","state_display":"California","zip":"92130","country":"US","country_display":"United States of America","ppb_country":"US","ppb_country_display":"United States of America","contact_name":"CHRISTOPHER PORTER","contact_telephone":"+1 877-969-7879","dt_updated":"2026-07-20T10:56:00.116563-04:00"},"client":{"id":200929,"url":"https://lda.senate.gov/api/v1/clients/200929/","client_id":12,"name":"TRAVERE THERAPEUTICS","general_description":"Biopharmaceuticals","client_government_entity":false,"client_self_select":true,"state":"CA","state_display":"California","country":"US","country_display":"United States of America","ppb_state":"CA","ppb_state_display":"California","ppb_country":"US","ppb_country_display":"United States of America","effective_date":"2016-08-15"},"lobbying_activities":[{"general_issue_code":"HCR","general_issue_code_display":"Health Issues","description":"Legislation regarding the Orphan Drug Act and rare disease diagnosis, treatment, and care. Newborn Screening Saves Lives Act Reauthorization, H.R. 482, S 350. FY 2022 and FY 2023 CDC Appropriations for state newborn screening technical assistance and related Senate appropriations. H.R. 1692, S 250, Fairness in Orphan Drug Exclusivity Act.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":64866,"prefix":null,"prefix_display":null,"first_name":"CHRISTOPHER","nickname":null,"middle_name":null,"last_name":"PORTER","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"PHA","general_issue_code_display":"Pharmacy","description":"H.R. 3, Elijah E. Cummings Lower Drug Costs Now Act and related Senate legislation. H.R. 19, Lower Costs More Cures Act. Legislative proposals regarding drug pricing, value, and reimbursement in H.R. 5736 Build Back Better Act and related Senate legislation. H.R. 7667, the Food and Drug Amendments of 2022 and related Senate legislation.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":64866,"prefix":null,"prefix_display":null,"first_name":"CHRISTOPHER","nickname":null,"middle_name":null,"last_name":"PORTER","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"MED","general_issue_code_display":"Medical/Disease Research/Clinical Labs","description":"H.R. 1730, S. 670, Speeding Therapy Access Today Act of 2021; H.R. 3893, Coordination, Accountability, Research, and Equity for All Kidneys Act of 2021. Congressional consideration of the Prescription Drug User Fee Act. H.R. 6963, Accelerated Approval Integrity Act, and H.R. 6996, Accelerated Access for Patient Act, and Senate proposals regarding expedited FDA pathways. H.R. 7506, the New Era of Preventing End-Stage Kidney Disease","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":64866,"prefix":null,"prefix_display":null,"first_name":"CHRISTOPHER","nickname":null,"middle_name":null,"last_name":"PORTER","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":34,"name":"Health & Human Services, Dept of (HHS)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"MMM","general_issue_code_display":"Medicare/Medicaid","description":"HR 366, Protecting Access to Post-COVID-19 Telehealth Act; other legislative proposals to ensure access to telehealth services","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":64866,"prefix":null,"prefix_display":null,"first_name":"CHRISTOPHER","nickname":null,"middle_name":null,"last_name":"PORTER","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"CPT","general_issue_code_display":"Copyright/Patent/Trademark","description":"S.1435 - Affordable Prescriptions for Patients Act of 2021, H.R.2873 Affordable Prescriptions for Patients Through Promoting Competition Act of 2021, and H.R.2884, Affordable Prescriptions for Patients Through Improvements to Patent Litigation Act; other 1egislation regarding intellectual property and trademark issues, including waivers of international trade agreements.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":64866,"prefix":null,"prefix_display":null,"first_name":"CHRISTOPHER","nickname":null,"middle_name":null,"last_name":"PORTER","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"TAX","general_issue_code_display":"Taxation/Internal Revenue Code","description":"Provisions of H.R. 5736 Build Back Better Act and related Senate legislation regarding the Orphan Drug Tax Credit; related rare disease research incentives. Legislation regarding tax treatment of net operating losses.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":64866,"prefix":null,"prefix_display":null,"first_name":"CHRISTOPHER","nickname":null,"middle_name":null,"last_name":"PORTER","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]}],"conviction_disclosures":[],"foreign_entities":[],"affiliated_organizations":[]}